226 related articles for article (PubMed ID: 37586771)
1. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.
Brito Baleeiro R; Liu P; Chard Dunmall LS; Di Gioia C; Nagano A; Cutmore L; Wang J; Chelala C; Nyambura LW; Walden P; Lemoine N; Wang Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586771
[TBL] [Abstract][Full Text] [Related]
2. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
[TBL] [Abstract][Full Text] [Related]
3. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
[TBL] [Abstract][Full Text] [Related]
4. Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model.
Kuryk L; Mathlouthi S; Wieczorek M; Gad B; Rinner B; Malfanti A; Mastrotto F; Salmaso S; Caliceti P; Garofalo M
Eur J Pharm Biopharm; 2024 Jun; 199():114300. PubMed ID: 38697488
[TBL] [Abstract][Full Text] [Related]
5. Neoantigen-augmented iPSC cancer vaccine combined with radiotherapy promotes antitumor immunity in poorly immunogenic cancers.
Huang KC; Chen WT; Chen JY; Lee CY; Wu CH; Lai CY; Yang PC; Liang JA; Shiau AC; Chao KSC; Ke TW
NPJ Vaccines; 2024 May; 9(1):95. PubMed ID: 38821980
[TBL] [Abstract][Full Text] [Related]
6. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.
De Mattos-Arruda L; Vazquez M; Finotello F; Lepore R; Porta E; Hundal J; Amengual-Rigo P; Ng CKY; Valencia A; Carrillo J; Chan TA; Guallar V; McGranahan N; Blanco J; Griffith M
Ann Oncol; 2020 Aug; 31(8):978-990. PubMed ID: 32610166
[TBL] [Abstract][Full Text] [Related]
7. Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy.
Guo Y; Lei K; Tang L
Front Immunol; 2018; 9():1499. PubMed ID: 30013560
[TBL] [Abstract][Full Text] [Related]
8. The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer.
Yan Z; Zhong Z; Shi C; Feng M; Feng X; Liu T
Cancer Biol Ther; 2024 Dec; 25(1):2355705. PubMed ID: 38778753
[TBL] [Abstract][Full Text] [Related]
9. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.
Perumal D; Imai N; Laganà A; Finnigan J; Melnekoff D; Leshchenko VV; Solovyov A; Madduri D; Chari A; Cho HJ; Dudley JT; Brody JD; Jagannath S; Greenbaum B; Gnjatic S; Bhardwaj N; Parekh S
Clin Cancer Res; 2020 Jan; 26(2):450-464. PubMed ID: 31857430
[TBL] [Abstract][Full Text] [Related]
10. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
[TBL] [Abstract][Full Text] [Related]
11. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology.
Panni UY; Chen MY; Zhang F; Cullinan DR; Li L; James CA; Zhang X; Rogers S; Alarcon A; Baer JM; Zhang D; Gao F; Miller CA; Gong Q; Lim KH; DeNardo DG; Goedegebuure SP; Gillanders WE; Hawkins WG
Cancer Immunol Immunother; 2023 Aug; 72(8):2813-2827. PubMed ID: 37179276
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic adenovirus encoding apolipoprotein A1 suppresses metastasis of triple-negative breast cancer in mice.
Dong J; Kong L; Wang S; Xia M; Zhang Y; Wu J; Yang F; Zuo S; Wei J
J Exp Clin Cancer Res; 2024 Apr; 43(1):102. PubMed ID: 38566092
[TBL] [Abstract][Full Text] [Related]
13. CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy.
Huff AL; Longway G; Mitchell JT; Andaloori L; Davis-Marcisak E; Chen F; Lyman MR; Wang R; Mathew J; Barrett B; Rahman S; Leatherman J; Yarchoan M; Azad NS; Yegnasubramanian S; Kagohara LT; Fertig EJ; Jaffee EM; Armstrong TD; Zaidi N
JCI Insight; 2023 Dec; 8(23):. PubMed ID: 38063199
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of neoantigen-reactive T cells combined with PD1 inhibitor therapy in mouse lung cancer.
Qin H; Hu H; Liao X; Zhao P; He W; Su X; Sun J; Li Q
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7363-7378. PubMed ID: 36933035
[TBL] [Abstract][Full Text] [Related]
15. Recent progress in combination therapy of oncolytic vaccinia virus.
Mirbahari SN; Da Silva M; Zúñiga AIM; Kooshki Zamani N; St-Laurent G; Totonchi M; Azad T
Front Immunol; 2024; 15():1272351. PubMed ID: 38558795
[TBL] [Abstract][Full Text] [Related]
16. Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.
D'Alise AM; Leoni G; Cotugno G; Siani L; Vitale R; Ruzza V; Garzia I; Antonucci L; Micarelli E; Venafra V; Gogov S; Capone A; Runswick S; Martin-Liberal J; Calvo E; Moreno V; Symeonides SN; Scarselli E; Bechter O
Clin Cancer Res; 2024 Jun; 30(11):2412-2423. PubMed ID: 38506710
[TBL] [Abstract][Full Text] [Related]
17. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
Rojas LA; Sethna Z; Soares KC; Olcese C; Pang N; Patterson E; Lihm J; Ceglia N; Guasp P; Chu A; Yu R; Chandra AK; Waters T; Ruan J; Amisaki M; Zebboudj A; Odgerel Z; Payne G; Derhovanessian E; Müller F; Rhee I; Yadav M; Dobrin A; Sadelain M; Łuksza M; Cohen N; Tang L; Basturk O; Gönen M; Katz S; Do RK; Epstein AS; Momtaz P; Park W; Sugarman R; Varghese AM; Won E; Desai A; Wei AC; D'Angelica MI; Kingham TP; Mellman I; Merghoub T; Wolchok JD; Sahin U; Türeci Ö; Greenbaum BD; Jarnagin WR; Drebin J; O'Reilly EM; Balachandran VP
Nature; 2023 Jun; 618(7963):144-150. PubMed ID: 37165196
[TBL] [Abstract][Full Text] [Related]
18. An oncolytic virus-delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment.
DePeaux K; Rivadeneira DB; Lontos K; Dean VG; Gunn WG; Watson MJ; Yao T; Wilfahrt D; Hinck C; Wieteska L; Thorne SH; Hinck AP; Delgoffe GM
J Exp Med; 2023 Oct; 220(10):. PubMed ID: 37552475
[TBL] [Abstract][Full Text] [Related]
19. Self-assembled nanoparticles based on DNA origami and a nitrated T helper cell epitope as a platform for the development of personalized cancer vaccines.
Kang Y; Zhang W; Yu Q; Gao L; Quan J; Gu F; Wu Y; Tian Y; Wu Z; Shao S; Zhou H; Duan S; Zhou Y; Zhang L; Gao X; Tian H; Yao W
Cancer Immunol Immunother; 2023 Aug; 72(8):2741-2755. PubMed ID: 37119260
[TBL] [Abstract][Full Text] [Related]
20. Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.
Wang LC; Lynn RC; Cheng G; Alexander E; Kapoor V; Moon EK; Sun J; Fridlender ZG; Isaacs SN; Thorne SH; Albelda SM
Mol Ther; 2012 Apr; 20(4):736-48. PubMed ID: 22008913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
